TrovaGene Inc  

(Public, NASDAQ:TROVU)   Watch this stock  
Find more results for TROVU
+0.91 (5.14%)
Apr 11 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 13.30 - 17.69
Open     -
Vol / Avg. 0.00/0.00
Mkt cap 159.16M
P/E     -
Div/yield     -
EPS -1.10
Shares 1.67M
Beta -99.74
Inst. own 590%
Aug 4, 2016
Q2 2016 Trovagene Inc Earnings Call - 5:00PM EDT - Add to calendar
Aug 4, 2016
Q2 2016 Trovagene Inc Earnings Release - 4:00PM EDT - Add to calendar
Jul 13, 2016
Trovagene Inc at Cantor Fitzgerald Healthcare Conference - Webcast
May 17, 2016
Trovagene Inc Annual Shareholders Meeting
May 10, 2016
Q1 2016 Trovagene Inc Earnings Call
May 10, 2016
Q1 2016 Trovagene Inc Earnings Release
May 4, 2016
Trovagene Inc at Deutsche Bank Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -8517.32% -8782.04%
Operating margin -8680.09% -8079.55%
EBITD margin - -7958.49%
Return on average assets -59.89% -54.75%
Return on average equity -91.67% -96.39%
Employees 72 -
CDP Score - -


11055 Flintkote Ave
SAN DIEGO, CA 92121-1220
United States - Map
+1-858-2175420 (Phone)
+1-858-2174768 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.

Officers and directors

Thomas H. Adams Jr. Ph.D. Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
William J. Welch Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Paul R. Billings M.D., Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
John P. Brancaccio Independent Director
Age: 67
Bio & Compensation  - Reuters
Gary S. Jacob Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
Rodney S. Markin M.D., Ph.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Stanley N. Tennant Independent Director
Age: 63
Bio & Compensation  - Reuters